{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:25:22Z","timestamp":1784715922068,"version":"3.55.0"},"reference-count":26,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,5,7]]},"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomised controlled trial with blinded assessment of primary outcome variable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Outpatient primary healthcare population from 5 New Zealand sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>138 adults aged \u226516, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of \u22652. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8\u2005weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary outcome measure was the proportion of participants who had a \u22652 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100\u2005mm scale (0\u2005mm \u2018much worse\u2019, 100\u2005mm \u2018much improved\u2019) at weeks 2 and 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>24\/68 (34.3%) in the Honevo group and 12\/69 (17.4%) in the control group had a \u22652 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was \u22121 (Hodges-Lehman estimate, 95% CI \u22121 to 0, p=0.03), and at week 8 minus baseline was \u22121 (Hodges-Lehman estimate, 95% CI \u22121 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)\u00b8 p&lt;0.001 for Honevo compared to control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Honevo is an effective treatment for rosacea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-007651","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T21:26:00Z","timestamp":1435181160000},"page":"e007651","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Randomised controlled trial of topical kanuka honey for the treatment of rosacea"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-3027","authenticated-orcid":false,"given":"Irene","family":"Braithwaite","sequence":"first","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hunt","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Riley","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fingleton","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janwillem","family":"Kocks","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Corin","sequence":"additional","affiliation":[{"name":"Clinical Horizons, Tauranga, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Helm","sequence":"additional","affiliation":[{"name":"Clinical Horizons, Tauranga, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davitt","family":"Sheahan","sequence":"additional","affiliation":[{"name":"Papamoa Pines Medical Centre, Tauranga, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tofield","sequence":"additional","affiliation":[{"name":"Cameron Medical Clinic, Tauranga, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Optimal Clinical Trials, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holliday","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[{"name":"University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beasley","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"2025121601160964000_5.6.e007651.1","doi-asserted-by":"publisher","DOI":"10.1159\/000082564"},{"key":"2025121601160964000_5.6.e007651.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"2025121601160964000_5.6.e007651.3","first-page":"419","article-title":"An epidemiological study of rosacea","volume":"69","author":"Berg","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"2025121601160964000_5.6.e007651.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042829"},{"key":"2025121601160964000_5.6.e007651.5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"2025121601160964000_5.6.e007651.6","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ , Kramer S , Carter B , et al . Interventions for rosacea. Cochrane Database Syst Rev 2011;(3):CD003262.","DOI":"10.1002\/14651858.CD003262.pub4"},{"key":"2025121601160964000_5.6.e007651.7","first-page":"57","article-title":"Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%","volume":"79","author":"Elewski","year":"2007","journal-title":"Cutis"},{"key":"2025121601160964000_5.6.e007651.8","unstructured":"World Health O. Antimicrobial resistance: global report on surveillance 2014. 2014; Report No. ISBN: 978 92 4 156474 8 Contract No. Document Number."},{"key":"2025121601160964000_5.6.e007651.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2096"},{"key":"2025121601160964000_5.6.e007651.10","unstructured":"Department of Health UKSMAC. The path of least resistance. http:\/\/antibiotic-action.com\/wp-content\/uploads\/2011\/07\/Standing-Medical-Advisory-Committee-The-path-of-least-resistance-1998.pdf [accessed January 2015] 1998."},{"key":"2025121601160964000_5.6.e007651.11","unstructured":"Wu Q . Antimicrobial effect of Manuka honey and Kanuka honey alone and in combination with the bioactives against the growth of Propionibacterium acnes ATCC 6919: a thesis submitted in partial fulfilment of the requirements for the degree Master of Food Technology. Albany, New Zealand, Massey University, 2011."},{"key":"2025121601160964000_5.6.e007651.12","doi-asserted-by":"crossref","first-page":"e55898","DOI":"10.1371\/journal.pone.0055898","article-title":"The effect of New Zealand kanuka, manuka and clover honeys on bacterial growth dynamics and cellular morphology varies according to the species","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS ONE"},{"key":"2025121601160964000_5.6.e007651.13","doi-asserted-by":"publisher","DOI":"10.1177\/1753425911422263"},{"key":"2025121601160964000_5.6.e007651.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1991.tb03186.x"},{"key":"2025121601160964000_5.6.e007651.15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/08923973.2011.641974","article-title":"Arabinogalactan proteins contribute to the immunostimulatory properties of New Zealand honeys","volume":"34","author":"Gannabathula","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2025121601160964000_5.6.e007651.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08028.x"},{"key":"2025121601160964000_5.6.e007651.17","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70065-2"},{"key":"2025121601160964000_5.6.e007651.18","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"2025121601160964000_5.6.e007651.19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/fct.12057","article-title":"Topical kanuka honey for the treatment of rosacea","volume":"18","author":"Fingleton","year":"2013","journal-title":"Focus Altern Complement Ther"},{"key":"2025121601160964000_5.6.e007651.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2004.09113.x"},{"key":"2025121601160964000_5.6.e007651.21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-1976","article-title":"Health-related quality of life in patients with cutaneous rosacea: a systematic review","volume":"95","author":"Van der Linden","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2025121601160964000_5.6.e007651.22","unstructured":"(Datapharm) ew. Cetomacrogol Cream BP 1988 Formula A. https:\/\/wwwmedicinesorguk\/emc\/medicine\/25140 (accessed 24 Dec 2014)."},{"key":"2025121601160964000_5.6.e007651.23","unstructured":"Kingdom NNHSU. Cetomacrogol Cream Formula A. http:\/\/wwwnhsuk\/medicine-guides\/pages\/MedicineOverviewaspx?medicine=Cetomacrogol%20Cream%20Formula%20A (accessed 24 Dec 2014)."},{"key":"2025121601160964000_5.6.e007651.24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2133.2011.10473.x","article-title":"Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review","volume":"165","author":"van Zuuren","year":"2011","journal-title":"Br J Dermatol"},{"issue":"(3 Suppl)","key":"2025121601160964000_5.6.e007651.25","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00005373-199603001-00030","article-title":"In vivo effects of tumor necrosis factor-alpha on incised wound and gunshot wound healing","volume":"40","author":"Fu","year":"1996","journal-title":"J Trauma"},{"key":"2025121601160964000_5.6.e007651.26","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199002000-00002"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-007651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:16:19Z","timestamp":1765876579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-007651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,24]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1136\/bmjopen-2015-007651"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-007651","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}